Featured

CD73 and PD-1 gatekeep self-reactive CD4+ T cell expansion

T cell tolerance to self antigens is essential for the prevention of autoreactivity, and negative selection in the thymus is partially responsible for this process. However, at least one-third of CD4+ T cells reactive to a self antigen escape clonal...

Read More

In the Spotlight...

Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling

Ogishi and Kitaoka et al. demonstrated that the PD-1/PD-L1 axis was essential for optimal humoral immunity through T cell-dependent and B cell-intrinsic mechanisms. Patients with PD-1 or PD-L1 deficie...

IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells

Fesneau et al. showed that in HNSCC and CRC tumors, expression of the inhibitor NKG2A, a receptor for HLA-E that is associated with poor prognosis for many solid cancers, was upregulated upon differen...

IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines

An effective scaffold-based vaccine (Vax) promoted massive and preferential monocyte expansion in the LNs. Addition of IL-2/anti-IL-2 (IL-2cx) significantly improved LN cDC1 expansion and activation w...

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response

Guégan et al. analyzed tumor samples from 166 lung adenocarcinoma patients treated with immune checkpoint inhibitors (ICI) to evaluate the predictive value of CD8+ T cell exhaustion on responsiveness ...
See all for this week

Previous Digests

A tetraspecific NK cell engager armed with IL-2v targets B-NHL

November 27, 2024

To capitalize on the antitumor potential of NK cells for the treatment of B cell non-Hodgkin lymphoma (B-NHL), Demaria et al. developed a clinical-grade tetraspecific NK cell engager (NKCE) that targets NKp46 and CD16a on NK cells and CD2...

SITC - 39th Annual Meeting 2024

November 20, 2024

This week’s extensive special feature covers select talks from the SITC - 39th Annual Meeting 2024 in Houston, TX. We have organized the content by topics below. Keynote lectureRafi Ahmed Harnessing innate immunityEric VivierNicholas Huntington Cancer vaccinesElizabeth M. JaffeeCathy...

Novel vaccine strategy uses bacteria to deliver cancer neoantigens

November 13, 2024

In cancer immunotherapy, vaccination with tumor-specific neoantigens can be an effective way to induce antitumor immunity. In recent work, Redenti and Im et al. developed a novel system to deliver neoantigens using an engineered probiotic E. coli Nissle 191...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Llambi

Gaelle Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

 — Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials

Current Sponsors

Past Sponsors
Close Modal

Subscribe to our mailing list

GDPR Marketing Permissions

The Fritsch Foundation/ACIR.org will use the information you provide on this form to be in touch with you and to send you a weekly digest on cance immunotherapy. Click below to confirm that you want to receive the weekly digest by:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at contact@acir.org. We will treat your information with respect and will never share it with any third-parties. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.